|Day Low/High||112.86 / 114.13|
|52 Wk Low/High||101.36 / 132.13|
Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.
Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.
Eli Lilly posted stronger-than-expected second quarter earnings Tuesday, and boosted its full-year profit forecast, thanks in part to a surge in sales of its key diabetes treatment.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
U.S. stock futures point lower on Tuesday, the first day of a critical two-day meeting of the Federal Reserve, and ahead of quarterly earnings from tech giant Apple; the earnings calendar also includes reports from Merck, Procter & Gamble, Mastercard and AMD; Capital One says a hacker got access to the personal information of more than 100 million of its credit card customers and applicants.
- Revenue in the second quarter of 2019 grew 1 percent, driven by 6 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Basaglar, Emgality and Cyramza, contributed 13 percentage points of revenue growth and represented approximately 43 percent of total revenue.
Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival
BAQSIMI is expected to be available in U.S. pharmacies within one month
With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.
Jim Cramer says don't trade earnings season, invest in it -- and invest the time needed to be a smart, successful investor.
Jim Cramer weighs in on Bristol-Myers Squibb, Eli Lily, DuPont, Marvell Technology, General Motors, Kraft Heinz, Maxar Technologies, and more.
-Data from OVERCOME shed new light on migraine stigma by examining attitudes through the eyes of people who have not been diagnosed with migraine
-Data from OVERCOME showed that inconsistent care patterns, including high use of emergency department/urgent care settings, may be contributing to misdiagnosis, sub-optimal treatment and increased healthcare utilization(1)
-Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue(1)
The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.
Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?
Mike Harrington, senior vice president and general counsel, to retire at year end
INDIANAPOLIS, July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality ® (galcanezumab-gnlm) for the treatment of episodic cluster...
-Findings showed that nearly 1 in 5 people with migraine (19%) are currently using opioids to treat their disease, up from 16 percent in 2009(1,2)
INDIANAPOLIS, July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019.
Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of superiority, significantly reducing A1C from baseline in people...
- Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
The names include a veterinary drug concern plus companies with successful drugs on the market.
INDIANAPOLIS, June 19, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.
Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
INDIANAPOLIS, June 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA) as a...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.